Cargando…

EDA-Fibronectin Originating from Osteoblasts Inhibits the Immune Response against Cancer

Osteoblasts lining the inner surface of bone support hematopoietic stem cell differentiation by virtue of proximity to the bone marrow. The osteoblasts also modify their own differentiation by producing various isoforms of fibronectin (FN). Despite evidence for immune regulation by osteoblasts, ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossnagl, Stephanie, Altrock, Eva, Sens, Carla, Kraft, Sabrina, Rau, Katrin, Milsom, Michael D., Giese, Thomas, Samstag, Yvonne, Nakchbandi, Inaam A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5031442/
https://www.ncbi.nlm.nih.gov/pubmed/27653627
http://dx.doi.org/10.1371/journal.pbio.1002562
_version_ 1782454810133397504
author Rossnagl, Stephanie
Altrock, Eva
Sens, Carla
Kraft, Sabrina
Rau, Katrin
Milsom, Michael D.
Giese, Thomas
Samstag, Yvonne
Nakchbandi, Inaam A.
author_facet Rossnagl, Stephanie
Altrock, Eva
Sens, Carla
Kraft, Sabrina
Rau, Katrin
Milsom, Michael D.
Giese, Thomas
Samstag, Yvonne
Nakchbandi, Inaam A.
author_sort Rossnagl, Stephanie
collection PubMed
description Osteoblasts lining the inner surface of bone support hematopoietic stem cell differentiation by virtue of proximity to the bone marrow. The osteoblasts also modify their own differentiation by producing various isoforms of fibronectin (FN). Despite evidence for immune regulation by osteoblasts, there is limited knowledge of how osteoblasts modulate cells of the immune system. Here, we show that extra domain A (EDA)-FN produced by osteoblasts increases arginase production in myeloid-derived cells, and we identify α5β1 as the mediating receptor. In different mouse models of cancer, osteoblasts or EDA-FN was found to up-regulate arginase-1 expression in myeloid-derived cells, resulting in increased cancer growth. This harmful effect can be reduced by interfering with the integrin α5β1 receptor or inhibiting arginase. Conversely, in tissue injury, the expression of arginase-1 is normally beneficial as it dampens the immune response to allow wound healing. We show that EDA-FN protects against excessive fibrotic tissue formation in a liver fibrosis model. Our results establish an immune regulatory function for EDA-FN originating from the osteoblasts and identify new avenues for enhancing the immune reaction against cancer.
format Online
Article
Text
id pubmed-5031442
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-50314422016-10-10 EDA-Fibronectin Originating from Osteoblasts Inhibits the Immune Response against Cancer Rossnagl, Stephanie Altrock, Eva Sens, Carla Kraft, Sabrina Rau, Katrin Milsom, Michael D. Giese, Thomas Samstag, Yvonne Nakchbandi, Inaam A. PLoS Biol Research Article Osteoblasts lining the inner surface of bone support hematopoietic stem cell differentiation by virtue of proximity to the bone marrow. The osteoblasts also modify their own differentiation by producing various isoforms of fibronectin (FN). Despite evidence for immune regulation by osteoblasts, there is limited knowledge of how osteoblasts modulate cells of the immune system. Here, we show that extra domain A (EDA)-FN produced by osteoblasts increases arginase production in myeloid-derived cells, and we identify α5β1 as the mediating receptor. In different mouse models of cancer, osteoblasts or EDA-FN was found to up-regulate arginase-1 expression in myeloid-derived cells, resulting in increased cancer growth. This harmful effect can be reduced by interfering with the integrin α5β1 receptor or inhibiting arginase. Conversely, in tissue injury, the expression of arginase-1 is normally beneficial as it dampens the immune response to allow wound healing. We show that EDA-FN protects against excessive fibrotic tissue formation in a liver fibrosis model. Our results establish an immune regulatory function for EDA-FN originating from the osteoblasts and identify new avenues for enhancing the immune reaction against cancer. Public Library of Science 2016-09-21 /pmc/articles/PMC5031442/ /pubmed/27653627 http://dx.doi.org/10.1371/journal.pbio.1002562 Text en © 2016 Rossnagl et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Rossnagl, Stephanie
Altrock, Eva
Sens, Carla
Kraft, Sabrina
Rau, Katrin
Milsom, Michael D.
Giese, Thomas
Samstag, Yvonne
Nakchbandi, Inaam A.
EDA-Fibronectin Originating from Osteoblasts Inhibits the Immune Response against Cancer
title EDA-Fibronectin Originating from Osteoblasts Inhibits the Immune Response against Cancer
title_full EDA-Fibronectin Originating from Osteoblasts Inhibits the Immune Response against Cancer
title_fullStr EDA-Fibronectin Originating from Osteoblasts Inhibits the Immune Response against Cancer
title_full_unstemmed EDA-Fibronectin Originating from Osteoblasts Inhibits the Immune Response against Cancer
title_short EDA-Fibronectin Originating from Osteoblasts Inhibits the Immune Response against Cancer
title_sort eda-fibronectin originating from osteoblasts inhibits the immune response against cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5031442/
https://www.ncbi.nlm.nih.gov/pubmed/27653627
http://dx.doi.org/10.1371/journal.pbio.1002562
work_keys_str_mv AT rossnaglstephanie edafibronectinoriginatingfromosteoblastsinhibitstheimmuneresponseagainstcancer
AT altrockeva edafibronectinoriginatingfromosteoblastsinhibitstheimmuneresponseagainstcancer
AT senscarla edafibronectinoriginatingfromosteoblastsinhibitstheimmuneresponseagainstcancer
AT kraftsabrina edafibronectinoriginatingfromosteoblastsinhibitstheimmuneresponseagainstcancer
AT raukatrin edafibronectinoriginatingfromosteoblastsinhibitstheimmuneresponseagainstcancer
AT milsommichaeld edafibronectinoriginatingfromosteoblastsinhibitstheimmuneresponseagainstcancer
AT giesethomas edafibronectinoriginatingfromosteoblastsinhibitstheimmuneresponseagainstcancer
AT samstagyvonne edafibronectinoriginatingfromosteoblastsinhibitstheimmuneresponseagainstcancer
AT nakchbandiinaama edafibronectinoriginatingfromosteoblastsinhibitstheimmuneresponseagainstcancer